Related references
Note: Only part of the references are listed.Determining Amyloid-beta Positivity Using F-18-AZD4694 PET Imaging
Joseph Therriault et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Disease-Associated Tau Phosphorylation Hinders Tubulin Assembly within Tau Condensates
Adriana Savastano et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial
Lauri Wihersaari et al.
INTENSIVE CARE MEDICINE (2021)
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative
Thomas K. Karikari et al.
MOLECULAR PSYCHIATRY (2021)
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Joel Simren et al.
ALZHEIMERS & DEMENTIA (2021)
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
Thomas K. Karikari et al.
ALZHEIMERS & DEMENTIA (2021)
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum
Alexis Moscoso et al.
BRAIN (2021)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Elisabeth H. Thijssen et al.
NATURE MEDICINE (2020)
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Shorena Janelidze et al.
NATURE COMMUNICATIONS (2020)
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification
Nicolas R. Barthelemy et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Antoine Leuzy et al.
JAMA NEUROLOGY (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
Juan Lantero Rodriguez et al.
ACTA NEUROPATHOLOGICA (2020)
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
Marta Mila-Aloma et al.
ALZHEIMERS & DEMENTIA (2020)
18F-MK-6240 PET for early and late detection of neurofibrillary tangles
Tharick A. Pascoal et al.
BRAIN (2020)
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease
Nicolas R. Barthelemy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration
Alberto Benussi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
Niklas Mattsson-Carlgren et al.
BRAIN (2020)
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval
Martin Tolar et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
Jozef Hanes et al.
NEUROLOGY (2020)
Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
Kanta Horie et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease
Andrea L. Benedet et al.
BRAIN (2020)
Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life
Ruth E. Uhlmann et al.
NATURE NEUROSCIENCE (2020)
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected
Marc Suarez-Calvet et al.
EMBO MOLECULAR MEDICINE (2020)
Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease
Joana R. F. Santos et al.
JOURNAL OF NEURAL TRANSMISSION (2019)
A walk through tau therapeutic strategies
Santosh Jadhav et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Gil D. Rabinovici et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges
Rudy J. Castellani et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
Nicholas J. Ashton et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain
Ebru Ercan-Herbst et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography
Michelle M. Mielke et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
Spomenka Kidemet-Piskac et al.
CNS NEUROSCIENCE & THERAPEUTICS (2018)
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Akinori Nakamura et al.
NATURE (2018)
Tau Kinetics in Neurons and the Human Central Nervous System
Chihiro Sato et al.
NEURON (2018)
Biomarkers for Alzheimer's disease: current status and prospects for the future
K. Blennow et al.
JOURNAL OF INTERNAL MEDICINE (2018)
In vivo quantification of neurofibrillary tangles with [18F]MK-6240
Tharick A. Pascoal et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Current state of Alzheimer's fluid biomarkers
Jose Luis Molinuevo et al.
ACTA NEUROPATHOLOGICA (2018)
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Sebastian Palmqvist et al.
NATURE COMMUNICATIONS (2017)
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson et al.
JAMA NEUROLOGY (2017)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis
Sulantha Mathotaarachchi et al.
FRONTIERS IN NEUROINFORMATICS (2016)
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
William E. Klunk et al.
ALZHEIMERS & DEMENTIA (2015)
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2013)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
101 labeled brain images and a consistent human cortical labeling protocol
Arno Klein et al.
FRONTIERS IN NEUROSCIENCE (2012)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules
Laziza Amniai et al.
FASEB JOURNAL (2009)
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment
Miroslaw Brys et al.
NEUROBIOLOGY OF AGING (2009)
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Heiko Braak et al.
ACTA NEUROPATHOLOGICA (2006)
Correlation of cerebrospinal fluid levels of Tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease
H Hampel et al.
ARCHIVES OF NEUROLOGY (2005)
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects
K Buerger et al.
NEUROLOGY (2002)
CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease
K Blennow et al.
MOLECULAR NEUROBIOLOGY (2001)
CSF phosphorylated tau protein and mild cognitive impairment: a prospective study
H Arai et al.
EXPERIMENTAL NEUROLOGY (2000)
Share Paper
